MktsMarkets

ArriVent BioPharma, Inc.
NASDAQ: AVBPKey statistics
AVBP News
Stories mentioning AVBP from around the web — every one is an open thread, so give it a like or add your take.
Loading news…
Financial statements
As filed, straight from the 10-Q — up to 19 years of history, free, with every line item chartable.
| Line item | Q1 '26Mar 31 | Q4 '25Dec 31 | Q3 '25Sep 30 | Q2 '25Jun 30 | Q1 '25Mar 31 | Q4 '24Dec 31 | Q3 '24Sep 30 | Q2 '24Jun 30 |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | ||||||||
| Cost of Goods Sold | ||||||||
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | ||||||||
| Research & Development | 37,617 | 32,175 | 32,167 | 27,720 | 61,289 | 20,163 | 20,088 | 21,778 |
| Sales General & Admin | ||||||||
| Total Operating Expenses | 46,111 | 38,823 | 38,316 | 33,623 | 66,772 | 23,705 | 24,232 | 25,697 |
| Operating Income (Loss) | (46,111) | (38,823) | (38,316) | (33,623) | (66,772) | (23,705) | (24,232) | (25,697) |
| Interest Income | 3,668 | 3,823 | ||||||
| Interest Expense | ||||||||
| Other Expense | ||||||||
| Pretax Income | ||||||||
| Tax Provision | ||||||||
| Net Income (Loss) | (43,320) | (35,544) | (34,978) | (31,399) | (64,387) | (20,633) | (20,564) | (21,874) |
| Earnings Per Share (Basic) | (0.96) | (0.92) | (0.83) | (0.90) | (1.90) | (0.66) | (0.61) | (0.65) |
| Earnings Per Share (Diluted) | (0.96) | (0.92) | (0.83) | (0.90) | (1.90) | (0.66) | (0.61) | (0.65) |
| Weighted Average Shares Outstanding (Basic) | 45,068 | 38,463 | 41,913 | 35,006 | 33,899 | 31,469 | 33,582 | 33,502 |
| Weighted Average Shares Outstanding (Diluted) | 45,068 | 38,463 | 41,913 | 35,006 | 33,899 | 31,469 | 33,582 | 33,502 |
Scroll the table sideways for older periods — the line-item column and the period header stay put. Hover a row and use the chart handle to plot it over the full history.
About AVBP
ArriVent BioPharma, Inc. (NASDAQ: AVBP) is a stock listed on the Nasdaq Stock Market under the ticker symbol AVBP. It last traded at $13.01 (Nov 13, 2026, 4:00 PM ET), down 0.5% on the day. That gives ArriVent BioPharma a market capitalisation of $676.0M.
Over the past 52 weeks AVBP has traded between $11.36 and $35.83.
For the quarter ended Mar 31, 2026 it reported a net loss of $43.3M.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Mar 31, 2026 | — | -$43.3M |
| Dec 31, 2025 | — | -$35.5M |
| Sep 30, 2025 | — | -$35.0M |
| Jun 30, 2025 | — | -$31.4M |
From ArriVent BioPharma’s quarterly (10-Q) filings, in US dollars.
Take a break — play a market game
Seven free games built around the markets. No download, no sign-up: they run right here in your browser.
Latest News
Market news from around the web — every story is an open thread, so give it a like or add your take.
Loading news…